| 4.44 -0.19 (-4.1%) | 04-27 11:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.42 | 1-year : | 7.5 |
| Resists | First : | 5.5 | Second : | 6.42 |
| Pivot price | 4.2  |
|||
| Supports | First : | 4.11 | Second : | 3.26 |
| MAs | MA(5) : | 4.7  |
MA(20) : | 4.06 |
| MA(100) : | 3.91 |
MA(250) : | 3.8 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 56 |
D(3) : | 59.7 |
| RSI | RSI(14): 62.2 |
|||
| 52-week | High : | 6.75 | Low : | 1.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ATAI ] has closed below upper band by 31.6%. Bollinger Bands are 126.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.89 - 4.91 | 4.91 - 4.93 |
| Low: | 4.45 - 4.48 | 4.48 - 4.51 |
| Close: | 4.58 - 4.62 | 4.62 - 4.67 |
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
Mon, 27 Apr 2026
These 3 Psychedelic Stocks Activated After Trump's Executive Order - MarketBeat
Mon, 27 Apr 2026
AtaiBeckley and PsyPAN win silver for trial participant input - Stock Titan
Wed, 22 Apr 2026
[Form 4] AtaiBeckley Inc. Insider Trading Activity - Stock Titan
Wed, 22 Apr 2026
Reiterated Buy on Atai Beckley as Robust EMP-01 Phase IIa Data and Solid Cash Position Support $16 Price Target - TipRanks
Tue, 21 Apr 2026
Atai Beckley NV - Reuters
Sat, 11 Apr 2026
atai Life Sciences, Beckley Psytech get FDA breakthrough therapy status for BPL-003 - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 0 (M) |
| Shares Float | 365 (M) |
| Held by Insiders | 3.0285e+008 (%) |
| Held by Institutions | 3.8 (%) |
| Shares Short | 17,240 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1022e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 588 % |
| Return on Equity (ttm) | -30.8 % |
| Qtrly Rev. Growth | 4.09e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -248.4 |
| EBITDA (p.s.) | -2.77197e+007 |
| Qtrly Earnings Growth | -3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -103 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 11.68 |
| Dividend | 0 |
| Forward Dividend | 2.463e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|